SARS-COV-2 infections in inborn errors of immunity: A single center study.
SARS-COV-2 infections in inborn errors of immunity: A single center study.
复制标题
DOI：
10.3389/fimmu.2022.1035571
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
严重急性呼吸综合征冠状病毒2号(SARS-CoV-2)是一种引起2019年冠状病毒病的单链核糖核酸病毒(新冠肺炎)。在过去的几个月里，免疫学世界讨论的主要话题之一是，如果免疫缺陷患者感染了这种病毒，他们的情况会如何。到目前为止，关于新冠肺炎诊断为先天性免疫缺陷患者的较大队列的数据有限。在这里，我们回顾了来自西奈山免疫缺陷项目的113名患者的单中心队列中新冠肺炎感染的数据，这些患者在2020年1月至2022年6月期间有132例感染。这包括56名男性和57名女性，年龄范围为2-84岁(中位数42岁)。病死率3%。入院患者之间的比较显示，未接种疫苗的患者住院风险显著增加，接种疫苗的患者为4%，未接种疫苗的患者为40%；优势比为15.0(95%CI4.2-53.4；p<；0.00001)。此外，其中36名患者在接种疫苗后和感染前测定的COVID抗尖峰抗体水平具有很大的变异性。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-stranded RNA virus that causes coronavirus disease 2019 (COVID-19). One of the main topics of conversation in these past months in the world of immunology has been the issue of how patients with immune defects will fare if they contract this infection. To date there has been limited data on larger cohorts of patients with Inborn Errors of Immunity (IEI) diagnosed with COVID-19. Here, we review the data of COVID-19 infections in a single center cohort of 113 patients from the Mount Sinai Immunodeficiency program, who had 132 infections between January 2020 and June 2022. This included 56 males and 57 females, age range 2 - 84 (median 42). The mortality rate was 3%. Comparison between admitted patients revealed a significantly increased risk of hospitalization amongst the unvaccinated patients, 4% vaccinated vs 40% unvaccinated; odds ratio 15.0 (95% CI 4.2 – 53.4; p <0.00001). Additionally, COVID anti-spike antibody levels, determined in 36 of these patients post vaccination and before infection, were highly variable.
登录
查看更多内容
DOI：
10.1016/j.clim.2021.108803
发表时间：
2021-09
期刊：
Clinical immunology (Orlando, Fla.)
影响因子：
--
作者：
Harada K;Ho HE;Cunningham-Rundles C
通讯作者：
Cunningham-Rundles C
DOI：
10.1056/nejmoa2110345
发表时间：
2021-11-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Thomas SJ;Moreira ED Jr;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Polack FP;Zerbini C;Bailey R;Swanson KA;Xu X;Roychoudhury S;Koury K;Bouguermouh S;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Yang Q;Liberator P;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Gruber WC;Jansen KU;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
9.1
作者：
Delavari S;Abolhassani H;Abolnezhadian F;Babaha F;Iranparast S;Ahanchian H;Moazzen N;Nabavi M;Arshi S;Fallahpour M;Bemanian MH;Shokri S;Momen T;Sadeghi-Shabestari M;Molatefi R;Shirkani A;Vosughimotlagh A;Safarirad M;Sharifzadeh M;Pashangzadeh S;Salami F;Shirmast P;Rezaei A;Moeini Shad T;Mohraz M;Rezaei N;Hammarström L;Yazdani R;Aghamohamamdi A
通讯作者：
Aghamohamamdi A
DOI：
10.1056/nejmoa2101544
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Sadoff J;Gray G;Vandebosch A;Cárdenas V;Shukarev G;Grinsztejn B;Goepfert PA;Truyers C;Fennema H;Spiessens B;Offergeld K;Scheper G;Taylor KL;Robb ML;Treanor J;Barouch DH;Stoddard J;Ryser MF;Marovich MA;Neuzil KM;Corey L;Cauwenberghs N;Tanner T;Hardt K;Ruiz-Guiñazú J;Le Gars M;Schuitemaker H;Van Hoof J;Struyf F;Douoguih M;ENSEMBLE Study Group
通讯作者：
ENSEMBLE Study Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group